IQ EQ FUND MANAGEMENT IRELAND Ltd Lowers Position in Guardant Health, Inc. $GH
Insider Transactions at Guardant Health
In other news, CEO Helmy Eltoukhy sold 90,565 shares of the business’s stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $103.82, for a total transaction of $9,402,458.30. Following the sale, the chief executive officer directly owned 2,047,143 shares in the company, valued at approximately $212,534,386.26. The trade was a 4.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CTO Darya Chudova sold 5,451 shares of the stock in a transaction on Monday, December 15th. The stock was sold at an average price of $104.04, for a total value of $567,122.04. Following the completion of the transaction, the chief technology officer owned 7,012 shares in the company, valued at approximately $729,528.48. This represents a 43.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 434,627 shares of company stock valued at $45,592,052. Company insiders own 6.10% of the company’s stock.
Guardant Health Trading Up 3.5%
Shares of NASDAQ:GH opened at $101.85 on Friday. The business has a 50-day moving average price of $106.38 and a two-hundred day moving average price of $81.68. The stock has a market capitalization of $12.84 billion, a P/E ratio of -31.73 and a beta of 1.63. Guardant Health, Inc. has a 1-year low of $34.88 and a 1-year high of $120.74.
Wall Street Analyst Weigh In
Several research firms have recently commented on GH. Wells Fargo & Company boosted their price target on Guardant Health from $93.00 to $120.00 and gave the stock an “overweight” rating in a research report on Monday, December 15th. Citigroup boosted their target price on shares of Guardant Health from $100.00 to $135.00 and gave the stock a “buy” rating in a report on Thursday, December 11th. TD Cowen restated a “buy” rating on shares of Guardant Health in a report on Wednesday, January 7th. Mizuho set a $135.00 price objective on shares of Guardant Health in a research report on Friday, January 9th. Finally, Guggenheim increased their target price on shares of Guardant Health from $115.00 to $135.00 and gave the company a “buy” rating in a research report on Monday, January 26th. Twenty-one equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Guardant Health has an average rating of “Moderate Buy” and an average price target of $106.86.
- 3 Fast-Growing Stocks Analysts See Doubling in Price
Read Our Latest Report on Guardant Health
Guardant Health Profile
Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.
The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.
Featured Articles
- Five stocks we like better than Guardant Health
- NEW LAW: Congress Approves Setup For Digital Dollar?
- The day the gold market broke
- What a Former CIA Agent Knows About the Coming Collapse
- Your Bank Account Is No Longer Safe
- Buy this stock tomorrow?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Guardant Health Right Now?
Before you consider Guardant Health, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Guardant Health wasn’t on the list.
While Guardant Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
